Table 1. Review of the percentage of peripheral blood lymphocyte subsets in patients with PD and healthy controls.
| Peripheral blood lymphocytes | PD vs. control | Region: country |
|---|---|---|
| CD3+ T cell | ↑ (32) | Asia: Japan (11,12,16,20,21); China (26-33) |
| ns (11,12,15,17,19,20,22,23,25,29) | ||
| ↓ (13,16,18,24,26-28,30,31,33) | ||
| CD4+ T cell | ns (11,17,19,20,23,24,26,29) | Europe: Italy (13,15); Finland (17); Russia (18); Poland (19); Spain (22); German (23,25) |
| ↓ (12-14,16,18,22,27,28,30-33) | ||
| CD8+ T Cell | ↑ (12,22,32) | |
| ns (11,15-20,23,24,26,27,33) | ||
| ↓ (13,28,30,31) | ||
| CD19+ or CD20+ B cell | ns (19,24,25,26,27,33) | |
| ↓ (16,18,22) | ||
| CD16+CD56+ NK cell | ↑ (16,18,21,26,28,30) | America: Brazil (24) |
| ns (19,24,25,33) | ||
| ↓ (13) |
↑/↓: compared to the healthy controls, the increase or decrease of the percentages of peripheral blood lymphocytes in patients with PD is statistically significant. ns, no statistical significance; PD, Parkinson’s disease.